ARS Pharmaceuticals reported $72.2 million in U.S. net product revenue for neffy, its FDA- and EC-approved intranasal epinephrine, in its first full commercial year. Total 2025 revenue reached $84.3 million, backed by accelerating U.S. uptake, ex-U.S. collaboration income, and initial supply agreements. The company closed the year with $245 million in cash, cash equivalents, and short-term investments, guided to cash-flow break-even on its current plan, and outlined 2026 growth catalysts including expanded U.S. payer access, a larger specialty sales footprint, and continued global rollouts following approvals in China and Australia and a positive CHMP opinion for pediatric use in Europe. A Canadian decision is expected in the second quarter of 2026. On the clinical front, a U.S. post-marketing study in supervised anaphylaxis events is underway, and a Phase 2b trial in chronic spontaneous urticaria targets interim data in the back half of 2026.
The strategic question is whether neffy can redefine the epinephrine rescue market from device-driven habit to preference-driven choice without collapsing margins. ARS is spending heavily to make that case: 2025 SG&A of $230.1 million dwarfed product sales, reflecting a scaled DTC engine, a frictionless switch path via virtual prescribers, and an HCP push that has already delivered more than 22,500 prescribers, half of whom are writing repeat scripts. The company is targeting roughly 50% gross-to-net retention while pursuing unrestricted formulary status across remaining large payers and moving eight Medicaid programs to coverage without prior authorization.
Why this matters now is twofold. First, epinephrine is a true rescue category where fear of needles and device complexity can delay treatment. If a needle-free format improves carry and timely use, patient outcomes could benefit, and HCPs may recalibrate their default prescribing. Early real-world experience reported by allergists suggests outcomes comparable to intramuscular injection, but the ongoing 600-event post-marketing study will be pivotal in convincing skeptical clinicians and payers. Second, the commercial model itself is a bellwether: ARS is leaning into consumerization and access innovation—$0 copays for eligible patients, telehealth-enabled switching, and school stocking programs now spanning more than 9,000 institutions—to create demand pull while payer levers catch up.
For payers, the calculus turns on clinical parity and budget impact. With generic auto-injectors commoditized through aggressive rebating, achieving broad, restriction-free access at parity or premium economics will require robust RWE, decisive HCP advocacy, and proof that convenience translates into fewer severe events, ER visits, or multi-dose episodes. The 12–18 month shelf-life dynamic in epinephrine also creates a renewal cadence; ARS expects 2026 to benefit as 2025 scripts expire, testing the stickiness of a nasal-first preference and the sustainability of copay and DTC support.
Competitors are unlikely to cede share quietly. Incumbent auto-injector players can deploy price defense, contracting in schools and payers, and patient support to blunt switching. Potential rival needle-free entrants would further validate the segment while compressing price. ARS’s ex-U.S. partner strategy and royalty financing align with a broader industry pattern of capital-light global expansion and non-dilutive funding, but the U.S. core must cross from awareness to habitual prescribing to justify the commercial spend.
Medical Affairs teams across the industry should watch how rapidly practice patterns shift in allergy clinics, how RWE is curated and disseminated to address real-world use questions, and whether guideline bodies evolve to explicitly recognize intranasal epinephrine. Commercial leaders will track whether ARS’s direct-to-consumer plus telehealth playbook becomes a template for other rescue categories.
The next 12 months will reveal if renewals, payer wins, and Phase IV evidence can unlock operating leverage—and whether label expansion into urticaria can turn a rescue-centric product into a broader, higher-frequency franchise. The sharp test ahead: can convenience rewrite standard of care before price competition rewrites the margin story?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
